Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

OBJECTIVE: To conduct subset analyses of SPIRIT-P2 (NCT02349295) to investigate the efficacy and safety of ixekizumab versus placebo in three subgroups of patients with active psoriatic arthritis (PsA) according to the concomitant conventional synthetic disease-modifying antirheumatic drug (cDMARD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Nash, Peter, Behrens, Frank, Orbai, Ana-Maria, Rathmann, Suchitrita S, Adams, David H, Benichou, Olivier, Deodhar, Atul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135452/
https://www.ncbi.nlm.nih.gov/pubmed/30233812
http://dx.doi.org/10.1136/rmdopen-2018-000692

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135452/
https://www.ncbi.nlm.nih.gov/pubmed/30233812
http://dx.doi.org/10.1136/rmdopen-2018-000692

Ejemplares similares